Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12328
Title: Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training.
Austin Authors: Lee, A L;Hill, C J;Cecins, N;Jenkins, S;McDonald, Christine F ;Burge, Angela T ;Rautela, L ;Stirling, R G;Thompson, P J;Holland, A E
Affiliation: Physiotherapy, La Trobe University, 99 Commercial Road, Melbourne 3004, Victoria, Australia
Department of Medicine, Monash University, Melbourne 3800, Australia
Curtin University, Kent Street, Bentley, Perth 6102, Australia
Alfred Health, Commercial Road, Melbourne 3004, Victoria, Australia
Austin Health, 145 Studley Road, Heidelberg 3084, Victoria, Australia
Institute for Breathing and Sleep, Austin Health, 145 Studley Road, Heidelberg 3084, Victoria, Australia
Physiotherapy, Melbourne School of Health Sciences, The University of Melbourne, 161 Barry Street, Carlton 3010, Victoria, Australia
Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Hospital Avenue, Nedlands, Perth 6009, Australia
Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth 6009, Australia
Issue Date: 15-Jul-2014
Publication information: Respiratory Medicine 2014; 108(9): 1303-9
Abstract: The 6-min walk distance (6MWD) and incremental shuttle walk distance (ISWD) are clinically meaningful measures of exercise capacity in people with non-cystic fibrosis (CF) bronchiectasis, but the change in walking distance which constitutes clinical benefit is undefined. This study aimed to determine the minimal important difference for the 6MWD and ISWD in non-CF bronchiectasis.Thirty-seven participants with mean FEV1 70% predicted completed both field walking tests before and after an 8-week exercise program. The minimal important difference was calculated using a distribution-based and anchor-based method, with the global rating of change scale used.The mean change in 6MWD in participants who reported themselves to be unchanged was 10 m, compared to 36 m (small change) and 45 m (substantial change) (p = 0.01). For the ISWD, the mean change in participants who reported themselves to be unchanged was 33 m, compared to 54 m (small change) and 73 m (substantial change) (p = 0.04). The anchor-based method defined the minimal important difference for 6MWD as 24.5 m (AUC 0.76, 95% CI 0.61-0.91) and for ISWD as 35 m (AUC 0.88, 95% CI 0.73-0.99), based on participant's global rating of change. The distribution-based method indicated a value of 22.3 m for the 6MWD and 37 m for the ISWD. There was excellent agreement between the two methods for the 6MWD (kappa = 0.91) and the ISWD (kappa = 0.92).Small changes in 6MWD and ISWD may represent clinically important benefits in people with non-CF bronchiectasis. These data are likely to assist in the interpretation of change in exercise capacity following intervention.
Gov't Doc #: 25087836
URI: http://ahro.austin.org.au/austinjspui/handle/1/12328
DOI: 10.1016/j.rmed.2014.07.006
URL: https://pubmed.ncbi.nlm.nih.gov/25087836
Type: Journal Article
Subjects: Bronchiectasis
Exercise capacity
Minimal important difference
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Nov 25, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.